PTC Therapeutics (PTCT) said Friday that the European Commission has adopted the recommendation of the Committee for Medicinal Products for Human Use to not renew Translarna's marketing authorization for nonsense mutation Duchenne muscular dystrophy.
The commission indicated that under EU Directive 2001/83, individual member states in the European Union can still allow continued use of Translarna, the company said.
PTC Therapeutics said it plans to work on a country-by-country basis to continue marketing
Translarna, or ataluren, for Duchenne muscular dystrophy in the region.
Price: 54.98, Change: -0.01, Percent Change: -0.02
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.